- ANGLE said it was delighted to announce that the University Medical Centre Hamburg-Eppendorf together with the Medical University of Graz and the Science for Life Laboratory, Stockholm University had published results of work demonstrating that the company's Parsortix system can be used to measure the expression of ARV7 (androgen receptor splice variant 7) transcripts in later stage prostate cancer patients.

It said the research has been published in Clinical Chemistry and a copy of the publication was available on the company's website at

ANGLE said: 'Measurement of the expression of ARV7 on circulating tumor cells (CTCs) obtained from a blood test has previously been studied and found to correlate with patient response to novel hormone therapy (NHT) drugs (Enzalutamide and Abiraterone).

'Where ARV7 is positively expressed, patients are unlikely to respond to NHT and benefit from moving directly to taxane-based chemotherapies.

'Where ARV7 is not expressed, patients do better when receiving NHT first and only moving to chemotherapy subsequently.

'Researchers believe that an ARV7 test utilising the Parsortix system for CTC enrichment could provide key advantages over other approaches.'

These include:

- the ability to analyse mesenchymal CTCs, so called CK (cytokeratin) negative cells, which are not captured by other CTC systems. In their research, UKE, Graz and SciLifeLab found a population of CK negative ARV7 positive cells that would not have been detected with the other label-dependent enrichment methods tested.

- the ability to analyse the number of ARV7 transcripts on each CTC. Existing approaches are limited to the presence or absence of ARV7 in the whole population of cells or require elaborate technologies to isolate CTCs that are available only at a small number of specialised centres.

- the ability to analyse the proportion of CTCs with ARV7 transcripts. Using the Parsortix system, researchers were able to enumerate the numbers of CTCs with and without ARV7.

ANGLE also said independent research had suggested that, in addition to improved patient outcomes, avoiding the use of expensive NHT drugs when the patient was ARV7 positive had the potential to reduce the cost for healthcare resources.

It said a cost-benefit analysis published in the Journal of Clinical Oncology estimated that an ARV7 test costing $1,000 per patient would result in cost savings averaging $5,000 per patient, with cost saving of at least $20,000 per patient with a positive ARV7 result.

ANGLE founder and chief executive Andrew Newland said: 'The measurement of ARV7 in later stage prostate cancer patients is one of a few accepted clinical uses of CTCs and is already offered as a laboratory-developed test by a small number of centres.

'We believe that the Parsortix system has specific advantages in measurement of ARV7 and has the potential for wide adoption in therapy selection.'

At 9:48am: [LON:AGL] Angle PLC share price was +2p at 53.5p

Story provided by